A research team from the Faculty of Medicine at the Chinese University of Hong Kong (CUHK) has confirmed that a new treatment can prolong the progression-free survival of liver cancer patients.
Researchers corroborated that a treatment called Ablative Chemoembolization (ACE) has proved more effective in killing cancer cells than the conventional transarterial chemoembolization (cTACE).
In addition, ACE helps extend the median progression free survival to 28 months, almost triple the 10 months of cTACE, the researchers found.
The ACE treatment is recommended only to patients of liver cancer at intermediate stage with five or fewer tumors, the Hong Kong Economic Journal reports.
This current study is a Phase 1 study focusing on feasibility and treatment safety. The CUHK research team will undertake more in-depth studies regarding ACE.
The results have been published in Radiology, an international medical journal.
Liver cancer is the fifth most common cancer in Hong Kong.
In 2015, there were about 1,800 new cases of the cancer reported locally during the year, and there were about 1,600 deaths of such patients, data from the Hospital Authority’s Cancer Registry shows.
– Contact us at [email protected]